Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/artax-announces-first-patient-dosed-in-phase-2a-psoriasis-trial-evaluating-ax-158-302060157.html
https://www.prnewswire.com/news-releases/artax-granted-clinical-trial-authorization-for-ax-158-phase-2a-psoriasis-study-301982709.html
https://www.prnewswire.com/news-releases/artax-biopharma-announces-positive-phase-1-results-for-ax-158-companys-first-in-class-oral-immunomodulator-developed-to-treat-t-cell-mediated-diseases-301839514.html
https://www.prnewswire.com/news-releases/artax-biopharma-appoints-andre-hoekema-phd-to-companys-board-of-directors-301763985.html
https://www.prnewswire.com/news-releases/artax-biopharma-expands-companys-scientific-advisory-board-301678295.html
https://www.prnewswire.com/news-releases/artax-biopharma-closes-financing-to-advance-clinical-stage-first-in-class-oral-immunomodulator-to-treat-t-cell-mediated-diseases-301544425.html
https://www.prnewswire.com/news-releases/artax-biopharma-announces-first-in-human-dosing-in-phase-1-clinical-trial-for-ax-158-companys-first-in-class-oral-immunomodulator-to-treat-t-cell-mediated-diseases-301445270.html
https://www.prnewswire.com/news-releases/artax-biopharma-granted-mhra-clinical-trial-authorization-for-ax-158-301332053.html
https://www.prnewswire.com/news-releases/artax-biopharma-announces-issuance-of-us-composition-of-matter-patent-for-autoimmune-disease-program-ax-158-301133104.html#:~:text=CAMBRIDGE%2C%20Mass.%2C%20Sept.,158%2C%20the%20Company's%20lead%20autoimmune
https://www.prnewswire.com/news-releases/artax-biopharma-announces-the-formation-of-scientific-advisory-board-to-advance-autoimmune-disease-therapy-ax-158-301082763.html